Adial Pharma Q1 Net Loss $2.02M; Molteni Europe AD04 Deal; Going Concern Doubt
Adial Pharmaceuticals reported a net loss of $2.02 million for the first quarter of 2026, an improvement compared to $2.23 million in the same period last year. The company's cash and cash equivalents stood at $4.58 million as of March 31, 2026, but management noted that existing cash is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern. A collaboration framework agreement was established with Molteni Farmaceutici for the commercialization of AD04 in Europe, potentially valued at nearly $60 million in royalties and milestones. Additionally, the company raised approximately $315,000 through its At-the-Market (ATM) offering in Q1 2026, with an additional $782,000 raised post-period.
Key Highlights
- Q1 2026 net loss was $2,022,392, an improvement from $2,228,801 in Q1 2025.
- Cash and cash equivalents totaled $4,584,100 as of March 31, 2026.
- Entered collaboration framework with Molteni for AD04 in Europe, with potential value of nearly $60 million.
- Existing cash is not sufficient for next 12 months, raising substantial doubt about going concern.
- Research and development expenses decreased to $432,530 in Q1 2026 from $746,891 in Q1 2025.
- General and administrative expenses increased to $1,568,951 in Q1 2026 from $1,520,402 in Q1 2025.
- Sold 181,230 shares under ATM for net proceeds of $315,284 in Q1 2026.
- Sold 499,606 shares under ATM for net proceeds of $782,000 from April 1 to May 6, 2026.